Literature DB >> 30218397

Clinical management of Duchenne muscular dystrophy: the state of the art.

Sonia Messina1,2,3, Gian Luca Vita4.   

Abstract

INTRODUCTION: Duchenne muscular dystrophy (DMD) is a devastating, progressive neuromuscular disorder for which there is no cure. As the dystrophin gene is located on the X chromosome, DMD occurs predominately in males. DMD is caused by a lack of functional dystrophin protein resulting from mutations in the 2.2-Mb DMD gene, whichdisrupts the reading frame. Care considerations for DMD advocate a coordinated, multidisciplinary approach to the management of DMD in order to optimize management of the primary manifestations of DMD as well as any secondary complications that may arise.
METHODS: This review provides an overview of the multidisciplinary clinical management of DMD with regard to the respiratory, cardiology, orthopedic, and nutritional needs of patients with DMD. Recent advances in novel disease-modifying treatments for DMD are also discussed with specific reference to exon skipping and suppression of premature stop codons as promising genetic therapies.
RESULTS: The combination of multidisciplinary clinical management alongside novel gene therapiesoffers physicians a powerful armamentarium for the treatment of DMD.

Entities:  

Keywords:  Ataluren; Duchenne muscular dystrophy; Exon skipping; Multidisciplinary care

Mesh:

Year:  2018        PMID: 30218397     DOI: 10.1007/s10072-018-3555-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  65 in total

1.  Natural evolution of weight status in Duchenne muscular dystrophy: a retrospective audit.

Authors:  Léonie Martigne; Julia Salleron; Michèle Mayer; Jean-Marie Cuisset; Alain Carpentier; Véronique Neve; Vincent Tiffreau; Dominique Guimber; Frédéric Gottrand
Journal:  Br J Nutr       Date:  2011-01-28       Impact factor: 3.718

Review 2.  Nutrition Considerations in Duchenne Muscular Dystrophy.

Authors:  Jillian Davis; Emily Samuels; Lucille Mullins
Journal:  Nutr Clin Pract       Date:  2015-05-14       Impact factor: 3.080

3.  A mixed methods study of age at diagnosis and diagnostic odyssey for Duchenne muscular dystrophy.

Authors:  Siaw H Wong; Belinda J McClaren; Alison Dalton Archibald; Alice Weeks; Tess Langmaid; Monique M Ryan; Andrew Kornberg; Sylvia A Metcalfe
Journal:  Eur J Hum Genet       Date:  2015-01-28       Impact factor: 4.246

Review 4.  Pharmacological therapy for the prevention and management of cardiomyopathy in Duchenne muscular dystrophy: A systematic review.

Authors:  Basmah El-Aloul; Luis Altamirano-Diaz; Eugenio Zapata-Aldana; Rebecca Rodrigues; Monali S Malvankar-Mehta; Cam-Tu Nguyen; Craig Campbell
Journal:  Neuromuscul Disord       Date:  2016-10-11       Impact factor: 4.296

5.  Cardiac phenotype determines survival in Duchenne muscular dystrophy.

Authors:  David J Birnkrant; Erhan Ararat; Maroun J Mhanna
Journal:  Pediatr Pulmonol       Date:  2015-06-10

Review 6.  What's New in the Management of Neuromuscular Scoliosis.

Authors:  Jaysson T Brooks; Paul D Sponseller
Journal:  J Pediatr Orthop       Date:  2016-09       Impact factor: 2.324

Review 7.  Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

8.  The effect of posterior spinal fusion on respiratory function in Duchenne muscular dystrophy.

Authors:  W M Alexander; M Smith; B J C Freeman; L M Sutherland; J D Kennedy; P J Cundy
Journal:  Eur Spine J       Date:  2012-11-20       Impact factor: 3.134

9.  Long-Term Pulmonary Function in Duchenne Muscular Dystrophy: Comparison of Eteplirsen-Treated Patients to Natural History.

Authors:  T Bernard Kinane; Oscar H Mayer; Petra W Duda; Linda P Lowes; Stephanie L Moody; Jerry R Mendell
Journal:  J Neuromuscul Dis       Date:  2018

10.  206th ENMC International Workshop: Care for a novel group of patients - adults with Duchenne muscular dystrophy Naarden, The Netherlands, 23-25 May 2014.

Authors:  Jes Rahbek; Birgit F Steffensen; Kate Bushby; Imelda J M de Groot
Journal:  Neuromuscul Disord       Date:  2015-05-27       Impact factor: 4.296

View more
  11 in total

Review 1.  Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle.

Authors:  Giuseppe Vita; Gian Luca Vita; Olimpia Musumeci; Carmelo Rodolico; Sonia Messina
Journal:  Neurol Sci       Date:  2019-02-25       Impact factor: 3.307

2.  Restoration of Functional Full-Length Dystrophin After Intramuscular Transplantation of Foamy Virus-Transduced Myoblasts.

Authors:  Jinhong Meng; Nathan Paul Sweeney; Bruno Doreste; Francesco Muntoni; Myra McClure; Jennifer Morgan
Journal:  Hum Gene Ther       Date:  2020-01-10       Impact factor: 5.695

3.  Low human dystrophin levels prevent cardiac electrophysiological and structural remodelling in a Duchenne mouse model.

Authors:  Gerard A Marchal; Maaike van Putten; Arie O Verkerk; Simona Casini; Kayleigh Putker; Shirley C M van Amersfoorth; Annemieke Aartsma-Rus; Elisabeth M Lodder; Carol Ann Remme
Journal:  Sci Rep       Date:  2021-05-07       Impact factor: 4.379

Review 4.  Histopathology of Duchenne muscular dystrophy in correlation with changes in proteomic biomarkers.

Authors:  Margit Zweyer; Hemmen Sabir; Paul Dowling; Stephen Gargan; Sandra Murphy; Dieter Swandulla; Kay Ohlendieck
Journal:  Histol Histopathol       Date:  2021-12-07       Impact factor: 2.303

5.  Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates.

Authors:  Antonino Catalano; Gian Luca Vita; Federica Bellone; Maria Sframeli; Maria Grazia Distefano; Matteo La Rosa; Agostino Gaudio; Giuseppe Vita; Nunziata Morabito; Sonia Messina
Journal:  J Endocrinol Invest       Date:  2021-09-15       Impact factor: 4.256

6.  Impaired myocardial strain in early stage of Duchenne muscular dystrophy: its relation with age and motor performance.

Authors:  Lilia Oreto; Gian Luca Vita; Giuseppe Mandraffino; Scipione Carerj; Maria Pia Calabrò; Roberta Manganaro; Maurizio Cusmà-Piccione; Maria Chiara Todaro; Maria Sframeli; Maria Cinquegrani; Antonio Toscano; Giuseppe Vita; Sonia Messina; Concetta Zito
Journal:  Acta Myol       Date:  2020-12-01

7.  Proteomic profiling of the interface between the stomach wall and the pancreas in dystrophinopathy.

Authors:  Paul Dowling; Stephen Gargan; Margit Zweyer; Hemmen Sabir; Michael Henry; Paula Meleady; Dieter Swandulla; Kay Ohlendieck
Journal:  Eur J Transl Myol       Date:  2021-03-26

8.  A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy.

Authors:  Gian Luca Vita; Maria Sframeli; Norma Licata; Alessandra Bitto; Sara Romeo; Francesca Frisone; Annamaria Ciranni; Giovanni Pallio; Federica Mannino; M'Hammed Aguennouz; Carmelo Rodolico; Francesco Squadrito; Antonio Toscano; Sonia Messina; Giuseppe Vita
Journal:  Brain Sci       Date:  2021-01-16

Review 9.  Practical approach to respiratory emergencies in neurological diseases.

Authors:  Fabrizio Racca; Andrea Vianello; Tiziana Mongini; Paolo Ruggeri; Antonio Versaci; Gian Luca Vita; Giuseppe Vita
Journal:  Neurol Sci       Date:  2019-12-02       Impact factor: 3.307

Review 10.  Is it the right time for an infant screening for Duchenne muscular dystrophy?

Authors:  Gian Luca Vita; Giuseppe Vita
Journal:  Neurol Sci       Date:  2020-02-28       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.